SLG
VKTX icon

Stanley-Laman Group’s Viking Therapeutics VKTX Stock Holding History

Stanley-Laman Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-30,815
Closed -$256K – 281
2019
Q2 		$256K Buy
+30,815
New +$263K 0.06% 247

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Stanley-Laman Group's VKTX Position: Q3 2019 in Review

Stanley-Laman Group sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 30,815 shares — an estimated $256K sold.

Stanley-Laman Group first reported a position in VKTX in Q2 2019 and held it in 1 quarter. The position peaked at $256K in Q2 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

  • Stanley-Laman Group reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 30,815 Viking Therapeutics shares in Q3 2019, an estimated $256K.
  • Stanley-Laman Group first reported a position in Viking Therapeutics in Q2 2019 and held it in 1 quarter.
  • Stanley-Laman Group's Viking Therapeutics position peaked at $256K in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.